UK markets closed

Bio-Path Holdings, Inc. (BPTH)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.5200-0.1650 (-6.15%)
As of 01:54PM EDT. Market open.

Bio-Path Holdings, Inc.

4710 Bellaire Boulevard
Suite 210
Bellaire, TX 77401
United States
832 742 1357
https://www.biopathholdings.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10

Key executives

NameTitlePayExercisedYear born
Mr. Peter H. Nielsen MBACo-Founder, Chairman of the Board, CEO, President, CFO & Treasurer696.24kN/A1949
Mr. Douglas P. MorrisCo-Founder, Director of Investor Relations, Secretary & Director73.74kN/A1956
Mr. Michael Hickey M.B.A.VP of Clinical OperationsN/AN/AN/A
Mr. Anthony PriceSenior Vice President of Finance, Accounting & AdministrationN/AN/AN/A
Dr. Ana Tari Ashizawa Ph.D., MBASenior Vice President of Research, Development & Clinical DesignN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Corporate governance

Bio-Path Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.